Is AbCellera (ABCL) Quietly Rewriting Its Business Model With ABCL635’s Phase II Menopause Bet?

• AbCellera Biologics recently reported first-quarter 2026 results, with revenue rising to US$8.32 million and net loss narrowing slightly to US$43.17 million, while also presenting at the Bank of America Global Healthcare Conference in Las Vegas.
• The company’s progress with ABCL635 into Phase II for a nonhormonal menopause therapy, supported by promising Phase I safety and target engagement data, highlights a shift toward internally driven clinical assets that could reshape its longer-term business mix.
• We’ll now examine how ABCL635’s advance into Phase II for menopausal symptoms may influence AbCellera’s evolving investment narrative and risk profile.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

AbCellera Biologics Investment Narrative Recap

To own AbCellera, you need to believe its shift from a pure discovery platform toward internal drugs like ABCL635 can eventually justify ongoing losses and a rich revenue multiple. The latest quarter’s modest revenue improvement and slightly narrower net loss do not change the near term focus: Phase II data for ABCL635 in Q3 2026 is still the key catalyst, while continued cash burn and uncertain partner income remain the central risks.

The most relevant update here is the interim Phase I readout and advancement of ABCL635 into Phase II for menopausal symptoms, discussed alongside Q1 2026 results. The clean safety profile and strong target engagement now tie directly into the upcoming proof of concept data, which could influence how investors weigh the potential of AbCellera’s internal pipeline against its current unprofitability and competition from existing menopause treatments.

Yet behind this clinical progress, investors should also weigh the growing reliance on internal programs and the risk that unpredictable milestone and royalty revenue could...

Read the full narrative on AbCellera Biologics (it's free!)

AbCellera Biologics’ narrative projects $123.3 million in revenue and $17.5 million in earnings by 2028.

Uncover how AbCellera Biologics' forecasts yield a $9.83 fair value, a 136% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$250 million with positive earnings by 2028, which contrasts sharply with the current heavy spending and uncertain ABCL635 outcomes. These views may shift as the latest trial data and Q1 figures are absorbed, so it is worth comparing how your own expectations stack up against such bullish scenarios.

Explore 9 other fair value estimates on AbCellera Biologics - why the stock might be worth just $7.00!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbCellera Biologics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com